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Abstract: Introduction: Ubiquitin C-terminal hydrolase-L1 (UCH-L1) is one of the promising candidates, with an accept-
able diagnostic value for predicting head computed tomography (CT) scan findings. However, there has been
a controversy between studies and still, there is no general overview on this. Therefore, the current system-
atic review and meta-analysis attempted to estimate the value of UCH-L1 in predicting intracranial lesions in
traumatic brain injury (TBI). Methods: Two independent reviewers screened records from the search of four
databases Medline, Embase, Scopus and Web of Science. The data were analyzed in the STATA 14.0 statistical
program and the findings were reported as a standardized mean difference (SMD), summary receiver perfor-
mance characteristics curve (SROC), sensitivity, specificity, and diagnostic odds ratio with 95% confidence in-
terval (95% CI). Results: Finally, the data of 13 articles were entered into the meta-analysis. The mean serum
level of UCH-L1 was significantly higher in patients with CT-positive than in TBI patients with CT negative (SMD
= 1.67, 95% CI: 1.12 to 2.23, I2 = 98.1%; p <0.0001). The area under the SROC curve for UCH-L1 in the predic-
tion of intracranial lesions after mild TBI was 0.83 (95% CI: 0.80 to 0.86). Sensitivity, specificity and diagnostic
odds ratio of serum UCH-L1 was 0.97 (95% CI: 0.92 to 0.99), 0.40 (95% CI: 0.30 to 0.51) and 19.37 (95% CI: 7.25
to 51.75), respectively. When the analysis was limited to assessing the serum level of UCH-L1 within the first 6
hours after mild TBI, its sensitivity and specificity increased to 0.99 (95% CI: 0.94 to 1.0) and 0.44 (95% CI: 0.38
to 0.052), respectively. In addition, the diagnostic odds ratio of 6-hour serum level of UCH-L1 in the prediction
of intracranial lesions was 680.87 (95% CI: 50.50 to 9197.97). Conclusion: Moderate level of evidence suggests
that serum/plasma levels of UCH-L1 have good value in prediction of head CT findings. It was also found that
evaluation of serum/plasma level of UCH-L1 within the first 6 hours following TBI would increase its predictive
value. However, there is a controversy about the best cutoffs of the UCH-L1.
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raumatic brain injury (TBI) is one of the most com-
mon causes of death and disability with a global
prevalence of 8.4%. Incidence, prevalence, and years
of life lost due to TBI increased significantly from 1990 to
2016 (1). This increasing burden has led to a substantial
increase in the TBI-related emergency visits. Intracranial
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lesions caused by TBI are diagnosed mainly with imaging
assessments such as computed tomography (CT) scan and
magnetic resonance imaging (MRI). However, for two rea-
sons, the use of imaging techniques in emergency depart-
ments is not feasible. First, there is no access to CT scan and
MRI in all emergency departments, and secondly, Imaging is
not possible for all trauma patients. In addition, exposure to
ionizing radiation as a result of CT scan should not ignore (2,
3). Therefore, researchers are looking for other diagnostic or
screening modalities that can be used to detect the intracra-
nial lesion.
Patients with TBI are divided into three categories of mild,
moderate and severe, based on clinical evaluations, in partic-
ular, Glasgow coma scale (GCS). Mild TBI is the most preva-
lent and physicians are always in trouble when patients need
to go for radiography for further evaluation. Estimates have
shown that about 16% of mild TBI patients have intracra-
nial lesions (4). This means that if all mild TBI patients un-
dergo CT scan or MRI, 84% of these imaging is unneces-
sary. To reduce this excessive imaging, screening tests such as
serum biomarkers can be effective. Several biomarkers such
as S100-B and neuron-specific enolase have been proposed
to predict central nervous system injuries (5-7), but there is
still a controversy between literature, and researchers are still
looking for other biomarkers. Of these, ubiquitin C-terminal
hydrolase-L1 (UCH-L1) is one of the promising candidates
with an acceptable value in the prediction of intracranial le-
sions (8). However, there has been a contention between
studies and there is still no general overview of this area.
Therefore, the present systematic review and meta-analysis
attempted to evaluate the value of UCH-L1 in the prediction
of intracranial lesions in TBI patients.
2. Methods:
2.1. Search strategy
The present meta-analysis was designed to determine the
value of UCH-L1 in predicting of head CT findings. For this
purpose, an extensive search was performed in Medline (via
PubMed), Embase, Scopus, and Web of Science. The search
terms were related to TBI in combination with the UCH-L1.
The Medline search query is provided below. In addition,
the search was done manually in the bibliography of relevant
studies and review articles. Google’s search engine was also
searched for gray literature.
2.2. PubMed search query:
1- "Ubiquitin Thiolesterase"[mh] OR "Thiolesterase, Ubiq-
uitin"[tiab] OR "Ubiquitin C-Terminal Hydrolase"[tiab]
OR "C-Terminal Hydrolase, Ubiquitin"[tiab] OR "Hydro-
lase, Ubiquitin C-Terminal"[tiab] OR "Ubiquitin C Ter-
minal Hydrolase"[tiab] OR "Ubiquitin Carboxy-Terminal
Hydrolase"[tiab] OR "Carboxy-Terminal Hydrolase, Ubiqui-
tin"[tiab] OR "Hydrolase, Ubiquitin Carboxy-Terminal"[tiab]
OR "Ubiquitin Carboxy Terminal Hydrolase"[tiab] OR
"Ubiquitin C-Terminal Esterase"[tiab] OR "C-Terminal
Esterase, Ubiquitin"[tiab] OR "Esterase, Ubiquitin C-
Terminal"[tiab] OR "Ubiquitin C Terminal Esterase"[tiab] OR
"Ubiquitin Carboxy-Terminal Esterase"[tiab] OR "Carboxy-
Terminal Esterase, Ubiquitin"[tiab] OR "Esterase, Ubiquitin
Carboxy-Terminal"[tiab] OR "Ubiquitin Carboxy Terminal
Esterase"[tiab] OR "Ubiquitin Carboxyl-Terminal Hydro-
lase Isozyme L1"[tiab] OR "Ubiquitin Carboxyl Terminal
Hydrolase Isozyme L1"[tiab] OR "Parkinson Disease 5
Protein"[tiab] OR "PARK5 Protein"[tiab] OR "Neuron Cy-
toplasmic Protein 9.5"[tiab] OR "UCHL1 Protein"[tiab] OR
"Uch-L1 Protein"[tiab] OR "Uch L1 Protein"[tiab] OR "UCH-
L1"[tiab]
2- "Brain Concussion"[mh] OR "Brain Injuries"[mh] OR
"Brain Injuries, Traumatic"[mh] OR "Brain Concus-
sion"[tiab] OR "Brain Injuries"[tiab] OR "Brain Injuries,
Traumatic"[tiab] OR "Brain Concussions"[tiab] OR "Concus-
sion, Brain"[tiab] OR "Commotio Cerebri"[tiab] OR "Cere-
bral Concussion"[tiab] OR "Cerebral Concussions"[tiab] OR
"Concussion, Cerebral"[tiab] OR "Concussion, Intermedi-
ate"[tiab] OR "Intermediate Concussion"[tiab] OR "Interme-
diate Concussions"[tiab] OR "Concussion, Severe"[tiab] OR
"Severe Concussion"[tiab] OR "Severe Concussions"[tiab]
OR "Concussion, Mild"[tiab] OR "Mild Concussion"[tiab]
OR "Mild Concussions"[tiab] OR "Mild Traumatic Brain In-
jury"[tiab] OR "Injuries, Brain"[tiab] OR "Brain Injury"[tiab]
OR "Injury, Brain"[tiab] OR "Injuries, Acute Brain"[tiab] OR
"Acute Brain Injuries"[tiab] OR "Acute Brain Injury"[tiab]
OR "Brain Injury, Acute"[tiab] OR "Injury, Acute Brain"[tiab]
OR "Brain Injuries, Acute"[tiab] OR "Brain Lacerations"[tiab]
OR "Brain Laceration"[tiab] OR "Laceration, Brain"[tiab]
OR "Lacerations, Brain"[tiab] OR "Brain Injuries, Fo-
cal"[tiab] OR "Brain Injury, Focal"[tiab] OR "Focal Brain
Injury"[tiab] OR "Injuries, Focal Brain"[tiab] OR "Injury,
Focal Brain"[tiab] OR "Focal Brain Injuries"[tiab] OR "Brain
Injury, Traumatic"[tiab] OR "Traumatic Brain Injuries"[tiab]
OR "Trauma, Brain"[tiab] OR "Brain Trauma"[tiab] OR
"Brain Traumas"[tiab] OR "Traumas, Brain"[tiab] OR "TBI
(Traumatic Brain Injury)"[tiab] OR "Encephalopathy, Trau-
matic"[tiab] OR "Encephalopathies, Traumatic"[tiab] OR
"Traumatic Encephalopathies"[tiab] OR "Injury, Brain,
Traumatic"[tiab] OR "Traumatic Encephalopathy"[tiab] OR
"TBIs (Traumatic Brain Injuries)"[tiab] OR "TBI (Traumatic
Brain Injuries)"[tiab] OR "Traumatic Brain Injury"[tiab] OR
"TBI"[tiab]
3- #1 AND #2
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Figure 1: PRISMA flow diagram of present meta-analysis.
Figure 2: Assessment of risk of bias, applicability (A) and publication bias (B) among eligible studies. No publication bias was observed
(p=0.362).
2.3. Selection criteria
All of the observational studies on the predictive value of
UCH-L1 in the prediction of head CT findings were included.
Exclusion criteria were chronic exposure to head trauma,
penetrating TBI, non-traumatic injury, lack of data, and re-
views.
2.4. Data extraction and quality assessment
The method of summarizing data has been reported in our
previous meta-analyses study (9-23). Two independent re-
viewers screened records from the database. The potentially
relevant studies were assessed in detail and finally, based on
the selection criteria eligible studies were identified. The
reviewers recorded the type of study (cohort, case-control,
cross-sectional, etc.), the age range of patients, sample size
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Table 1: Summary characteristics of studies
Author; year; country Type of study Age* CT- / CT+ Male gender Sampling methods Time to sample# Method assay GCS
Bazarian; 2018; USA Cohort 18-98 1793/122 1107 Convenience 0 to 12 ELISA 9-15
Diaz-Arrastia; 2014;
USA
Cohort 37±14 40 / 31 150 NR 0 to 24 ELISA 14-15
Dickens; 2018; Finland
and UK
Cohort 18-91 95 / 114 152 NR 0 to 12 ELISA 13-15
Korley; 2016; USA Cohort 26-56 84 / 75 215 Convenience 0 to 24 ELISA 3-15
Korley; 2018; USA Cohort 24-61 63 / 44 78 Convenience 0 to 24 ELISA 3-15
Lewis; 2017; USA Trial 18-80 154 / 34 116 NR 0 to 24 ELISA 13-15
Mondello; 2016; USA Cohort 3.8±3.7 10 / 29 28 NR 0 to 24 ELISA 3-15
Papa; 2012; USA Cohort 18-89 77 / 28 64 Convenience 0 to 4 ELISA 9-15
Papa; 2016; USA Cohort 18-83 290 / 35 212 Convenience 0 to 24 ELISA 9-15
Papa; 2017; USA Cohort 0-21 134 / 17 100 Convenience 0 to 6 ELISA 9-15
Posti; 2016; Finland
and UK
Cohort 45.3±19.2 90 / 200 239 Consecutive 0 ELISA 3-15
Welch; 2016; USA Cohort 18-80 215 / 36 151 NR 0 to 6 ELISA 13-15
Welch; 2017; USA Cohort 18-80 134 / 33 102 NR 0 ELISA 9-15
*, Data are presented as mean ± standard deviation or age range. #, hours from Traumatic brain injury (TBI). CT: Computed
tomography; GCS: Glasgow coma scale of patients at admission; ELISA: Enzyme-linked immunosorbent assay; NR: Not reported.
Table 2: Quality assessment of included articles based on QUADAS-2 guideline
Author; year
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(number of CT positive and CT negative TBI patients), male
gender frequency, sampling method (random, consecutive,
convenience), the method of UCH-L1 assay, TBI severity and
outcomes. The severity of TBI was divided into three groups,
mild (GCS: 13 to 15), moderate (GCS: 9 to 12) and severe
(GCS: 3 to 8). The evaluated outcomes included the mean
serum level of UCH-L1 in both CT positive and CT negative
groups and the number of true positive (TB), true negative
(TN), false positive (FP) and false negative (FN).
In some articles, the mean serum level of UCH-L1 was re-
ported in the graphs. In these cases, using the Plot Digitizer
software (available at http://plotdigitizer.sourceforge.net/),
the mean and standard deviation of the serum level of this
biomarker were extracted. In addition, many articles were
not reported TP, TN, FP, and FN cases. Therefore, TP, TN,
FP, and FN were estimated using the reported sensitivity and
specificity. Quality control of the eligible studies was eval-
uated using the proposed method of Quality Assessment of
Diagnostic Accuracy Studies 2 (QUADAS-2) guideline (24).
2.5. Statistical Methods
Data were analyzed in the STATA 14.2 program. Meta-
analysis was performed in two sections. In the first part,
the mean serum level of UCH-L1 was compared in CT pos-
itive and CT negative groups. In this section, the standard-
ized mean difference (SMD) was calculated and finally, an
overall SMD with a 95% confidence interval (95% CI) was
reported. In the second section, using the TP, TN, FP, and
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Table 3: Sensitivity analysis for performance of serum level of ubiquitin C-terminal hydrolase L1 in detection of intracranial lesion (based on
computed tomography findings) in mild traumatic brain injuries
Variable Sensitivity Specificity Diagnostic score Diagnostic odds ratio
Age group
Children NA NA NA NA
Adult 0.96 (0.92 to 0.98) 0.39 (0.29 to 0.51) 2.82 (1.86 to 3.77) 16.72 (6.44 to 43.39)
Timing (hours after TBI)
0 to 6 0.99 (0.94 to 1.0) 0.44 (0.38 to 0.52) 6.52 (3.92 to 9.12) 680.87 (50.50 to 9197.97)
>6 NA NA NA NA
Overall 0.97 (0.92 to 0.99) 0.40 (0.30 to 0.51) 2.96 (1.98 to 3.95) 19.37 (7.25 to 51.75)
All data are presented with 95% confidence interval.
Figure 3: Forest plot for serum level of ubiquitin C-terminal hydro-
lase L1 in traumatic brain injury (TBI) subjects with positive com-
puted tomography (CT) findings compared to negative CT findings.
CI: Confidence interval; SMD: Standardized mean difference.
FN data, the summary receiver operating characteristic curve
(SROC), sensitivity, specificity, diagnostic score, and diagnos-
tic odds ratio of UCH-L1 in the prediction of CT findings were
reported. I2 test was used to assess heterogeneity and Eager’s
test was used to evaluate the publication bias. In all analyzes
p <0.05 was defined as significant level.
3. Results:
3.1. Study characteristics
Finally, 13 articles provided data suitable for meta-analysis
(Figure 1) (8, 25-36). They were 12 cohort studies and 1 ob-
servational trial. These studies included 3977 patients with
TBI. CT scan findings in 3179 (79.93%) patients were negative
and in 798 (20.07%) were positive. The serum sample was ob-
tained in five studies during the first 6 hours after the onset
of TBI. In two studies, it was assessed within 12 hours and in
six studies over the first 24 hours after TBI. Four studies were
conducted on mild TBI, five with mild to moderate TBI and
four with mild to severe TBI patients. Table 1 shows a sum-
mary of the eligible studies.
3.2. Quality control and risk of bias
Quality assessment of the relevant studies according to the
QUADAS-2 guidelines showed that the risk of bias in patient
selection was high or unclear in 12 studies. Other items in
all studies were rated as the Low risk of bias (Figure 2A and
Table 2). There was no publication bias in the present study
(p = 0.362) (Figure 2B).
3.3. Meta-analysis
Comparison of mean serum/plasma UCH-L1 in CT positive
and CT negative patients
The mean value of serum/plasma levels of UCH-L1 reported
in each of the 13 papers were investigated (8, 25-36). The
analyzes showed that the mean serum/plasma level of
UCH-L1 was significantly higher in CT-positive TBI than
in CT negative TBI patients (SMD = 1.67, 95% CI: 1.12 to
2.23, p <0.0001; I2 = 98.1%, p < 0.0001) (Figure 3). The mean
serum/plasma level of UCH-L1 within 6 hours after TBI
(SMD = 1.72, 95% CI: 0.98 to 2.47, p <0.0001), during the first
12 hours after injury (SMD = 1.74, 95% CI: 0.42 to 3.07, p =
0.01) and 24 hours later (SMD = 1.55, 95% CI: 0.88 to 2.21, p
<0.0001) in CT positive TBI patients were always higher than
CT negative patients.
Screening performance characteristics in the detection of
an intracranial lesion in mild TBI
Six studies, including 15 separate experiments evaluated the
performance of UCH-L1 in the prediction of intracranial le-
sions (8, 25, 26, 29, 30, 33). The cut off used in the studies var-
ied between 41 pg/ml and 327 pg/ml. 11 experiments were
performed on mild TBI, three experiments on mild to moder-
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Figure 4: Summary of receiver operating curve (SROC) of serum level of ubiquitin C-terminal hydrolase L1 in detection of intracranial le-
sion (based on computed tomography findings) in mild and mild to severe traumatic brain injuries (TBI). AUC: Area under the curve; Sens:
Sensitivity; Spec: Specificity.
ate TBI and one experiment on mild to severe TBI. Therefore,
the analyzes of this section focused on mild TBI. The area un-
der the SROC curve for serum/plasma UCH-L1 in the predic-
tion of intracranial lesions after mild TBI was 0.83 (95% CI:
0.80 to 0.86) (Figure 4). The sensitivity and specificity of this
serum biomarker were 0.97 (95% CI: 0.92 to 0.99) and 0.40
(95% CI: 0.30 to 0.51), respectively. The Diagnostic odds ratio
of UCH-L1 in the prediction of intracranial lesions after mild
TBI was 19.37 (95% CI: 7.25 to 51.75) (Figure 5). When the
analysis was limited to assessing the serum/plasma UCH-L1
level within the first 6 hours after mild TBI, its sensitivity and
specificity increased to 0.99 (95% CI: 0.94 to 1.0) and 0.44
(95% CI: 0.38 to 0.052), respectively. The diagnostic odds ra-
tio of 6-hour UCH-L1 in the prediction of intracranial lesions
was 680.87 (95% CI: 50.50 to 9197.97) (Table 3).
4. Discussion:
The present meta-analysis showed that after TBI, the
serum/plasma UCH-L1 level increased significantly. There-
fore, it could be used as a biomarker to detect intracranial
lesions. The area under the SROC of UCH-L1 in prediction
of head CT scan findings was 0.83. Serum/plasma UCH-L1
has a high sensitivity (0.97) to predict intracranial lesions but
its specificity (0.40) is low. Since the role of using biomark-
ers in the clinic is more focused on its screening value, the
high sensitivity of UCH-L1 in predicting intracranial lesions
is an advantage, while its low specificity is not a major weak-
ness in the use of UCH-L1 in the management of TBI. How-
ever, it is necessary to introduce an optimum cut off for the
serum/plasma level of UCH-L1. The cut offs used in the stud-
ies were between 41 pg / ml and 327 pg / ml. Therefore, in
the current meta-analysis, the assessment of the best cut offs
for the UCH-L1 was not possible. Therefore, further stud-
ies are recommended. The diagnostic/predictive value of
biomarkers varies with time (37, 38). Since, decision making
in TBI patients is performed during the first 24 hours of in-
jury, the 24-hour serum/plasma UCH-L1 level was analyzed
in the current meta-analysis. The findings indicate that the
performance of UCH-L1 is higher in the first 6 hours of TBI
than in the next few hours. Therefore, it seems that evaluat-
ing this biomarker as soon as possible can provide valuable
information about the severity of TBI.
In a similar meta-analysis study, Shahjouei et al. showed that
the serum/plasma level of UCH-L1 has a moderate value in
the prediction of intracranial lesions (39). This report was
different from the findings of the present study. Shahjouei
et al., included data from four studies, while in the present
study, data from six studies containing 15 separate experi-
ments were entered. On the other hand, the conclusion pre-
sented by Shahjouei et al is based on the area under the curve
of UCH-L1, while our findings were presented based on TP,
TN. FP, and FN. In addition, the area under the curve simulta-
neously represents sensitivity and specificity. In the present
study, the UCH-L1 has a high sensitivity that is very suitable
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Figure 5: Performance of serum level of ubiquitin C-terminal hy-
drolase L1 in detection of intracranial lesion (based on computed to-
mography findings) in mild traumatic brain injuries. A) Sensitivity
and specificity; B) Diagnostic score and diagnostic odds ratio.
for a screening test, but has a low specificity that does not
play a critical role in screening of patients. Therefore, it is not
possible to accurately discuss about the value of a screening
biomarker just by reporting the AUC.
Many articles do not report TP, TN, FP, and FN and instead
provide sensitivity and specificity. To overcome this problem,
using standard methods and web-based applications, TP, TN,
FP, and FN were obtained from sensitivity and specificity.
This was one of the strengths of the present study. How-
ever, in the present study due to the high diversity among
eligible studies, it was not possible to report the best cut off
for serum/plasma level of UCH-L1. There was also a signif-
icant heterogeneity between studies. Unfortunately, we did
not find the source of heterogeneity. Therefore, for these rea-
sons, the evidence presented in this study was reduced to a
moderate level.
5. Conclusion
A moderate level of evidence suggests that the serum/plasma
level of UCH-L1 had good value in prediction of head CT
findings. It was also found that evaluation of serum/plasma
level of UCH-L1 within the first 6 hours after TBI would in-
crease its predictive value. However, there is a controversy
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